×
About 980 results

ALLMedicine™ Gastric Tumors Center

Research & Reviews  321 results

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT05541874

Mar 10th, 2023 - Gastric cancer is among the leading causes of cancer-related death worldwide. Surgery or radiation monotherapy are applicable as treatment for localized tumors, however, the majority of patients are diagnosed in an advanced disease state requiring...

Diagnostic criteria and endoscopic and histological findings of autoimmune gastritis in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998601
Journal of Gastroenterology; Kamada T, Watanabe H et. al.

Mar 2nd, 2023 - The Japanese diagnostic criteria for autoimmune gastritis (AIG) were established by the "Study Group on the establishment of diagnostic criteria for type A gastritis," which is related to a workshop associated with the Japan Gastroenterological En...

Gastroblastoma mimics the embryonic mesenchyme of the foregut: a case report.
https://doi.org/10.1186/s13000-023-01310-2
Diagnostic Pathology; Sugimoto R, Uesugi N et. al.

Feb 22nd, 2023 - Gastroblastoma is a rare gastric tumor composed of epithelial and spindle cell components. The characteristic MALAT-GLI1 fusion gene has only been identified in 5 reported cases. We report the morphological characterization of gastroblastoma with ...

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT03008278

Feb 13th, 2023 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
https://clinicaltrials.gov/ct2/show/NCT03027427

Feb 1st, 2023 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  20 results

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT05541874

Mar 10th, 2023 - Gastric cancer is among the leading causes of cancer-related death worldwide. Surgery or radiation monotherapy are applicable as treatment for localized tumors, however, the majority of patients are diagnosed in an advanced disease state requiring...

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT03008278

Feb 13th, 2023 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
https://clinicaltrials.gov/ct2/show/NCT03027427

Feb 1st, 2023 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study
https://clinicaltrials.gov/ct2/show/NCT02491840

Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...

Clinical Study of 68Ga Labeled HER2 Affibody Analogues
https://clinicaltrials.gov/ct2/show/NCT05411432

Jun 9th, 2022 - 6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 3, 5, 10, 3...

see more →

News  45 results

Risk factors for delayed gastric emptying following gastrectomy for gastric cancer
https://www.mdedge.com/hematology-oncology/article/258994/gastrointestinal-cancer/risk-factors-delayed-gastric-emptying

Oct 26th, 2022 - Key clinical point: The female sex, distal gastric tumors, and diabetes are risk factors for delayed gastric emptying (DGE) in patients who have undergone gastrectomy for gastric cancer. Major finding: Multivariate analysis revealed female sex (ad.

Perioperative Immunotherapy Demonstrates Promising pCR Rates in dMMR/MSI-H Gastric and GEJ Cancer
https://www.onclive.com/view/perioperative-immunotherapy-demonstrates-promising-pcr-rates-in-dmmr-msi-h-gastric-and-gej-cancer

Aug 22nd, 2022 - Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by adjuvant nivolumab elicited positive pathologic complete response (pCR) rates in patients with locally advanced resectable mismatch repair–deficient (dMMR) and/or microsatellite i...

Pre-Op Chemosensitivity Tied to Post-Op Survival in Patients With Gastric Tumors
https://www.medscape.com/viewarticle/964279

Dec 8th, 2021 - NEW YORK (Reuters Health) - How long patients with resected gastric adenocarcinoma survive is tied to their preoperative sensitivity to chemotherapy, researchers report. "Interestingly, in patients with sensitive tumors, there was a significant su...

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors
https://www.onclive.com/view/trastuzumab-deruxtecan-shows-promise-beyond-breast-and-gastric-tumors

Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...

Shah Highlights Novel Agents in Gastrointestinal Cancers
https://www.onclive.com/view/shah-highlights-novel-agents-in-gastric-cancer

Oct 6th, 2021 - Manish A. Shah, MD The GLOW and DESTINY-Gastric01 trials showcase 2 novel agents coming down the pipeline in the treatment paradigm for patients with gastric cancers, according to Manish A. Shah, MD. The ongoing phase 3 GLOW study is enrolling p...

see more →